|Dr. Isao Teshirogi||CEO, Pres & Representative Director||1.75M||N/A||1959|
|Ms. Takuko Yamada-Sawada||Exec. VP, Sr. VP of Integrated Disease Care Division & Director||877.37k||N/A||1955|
|Mr. Noriyuki Kishida||Sr. Exec. Officer & Sr. VP of Admin. Division||N/A||N/A||N/A|
|Mr. Yoshimasa Kyokawa||VP of Corp. Communications & Sec. Office||N/A||N/A||N/A|
|Yoshihiro Furuya||VP of Gen. Marketing and Compliance Officer of Corp. GXP Compliance Office||N/A||N/A||N/A|
|Mr. Kohji Hanasaki Ph.D.||Sr. Exec. Officer & Sr. VP of Corp. Strategy Division||N/A||N/A||N/A|
|Dr. John A. Keller||Sr. Exec. Officer & Sr. VP of Global Bus. Division||N/A||N/A||1965|
|Mr. Takeshi Shiota||SVP of Pharmaceutical Research Div, GM of Innovative Drug Discovery Research Labs & Corp Officer||N/A||N/A||N/A|
|Mr. Kazuhiro Hatanaka||Sr. Exec. Officer of Pharmaceutical Commercial Division||N/A||N/A||N/A|
|Akira Kato Ph.D.||Corp. Officer & GM of Bus. Devel. Department||N/A||N/A||N/A|
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. Its primary products Tivicay for HIV treatment; Mulpleta for the treatment of thrombocytopenia; Xofluza, an influenza drug; Symproic for opioid-induced constipation treatment; and Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment. The company also offers antibody detection kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with InveniAI, LLC.; Hsiri Therapeutics Inc.; Nagasaki University; Roche Group to develop and commercialize Xofluza; and Nagasaki University and The Kitasato Institute to develop antimalarial drugs and vaccines. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
Shionogi & Co., Ltd.’s ISS Governance QualityScore as of July 1, 2021 is 1. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 2; Compensation: 1.